Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992 Jul;10(2):93-6.
doi: 10.1007/BF00873123.

Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors. A phase II study (Pediatric Oncology Group)

R Nitschke  1 , C Pratt, M Harris, J Krischer, T J Vietti, H Grier, W Kamps, S Toledano
Affiliations
Clinical Trial

Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors. A phase II study (Pediatric Oncology Group)

R Nitschke et al. Invest New Drugs. 1992 Jul.

Abstract

CHIP (325 mg/M2), a second generation cisplatin derivative, was administered intravenously every 3 weeks to 85 pediatric patients with recurrent sarcomas (19), osteosarcomas (20), neuroblastoma (23), germ cell tumors (10), and other malignant tumors (7). Thirty-eight of them had been previously exposed to cisplatin. Partial remissions were only observed in 3 of 23 (13% SE = 7%) patients having neuroblastoma. Severe thrombocytopenia (65%) and neutropenia (35%) were the dose limiting factors.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Invest New Drugs. 1988 Sep;6(3):199-206 - PubMed
    1. Cancer Treat Rep. 1987 Jan;71(1):87-8 - PubMed
    1. Cancer Treat Rep. 1983 Sep;67(9):795-800 - PubMed
    1. Br J Cancer. 1983 Apr;47(4):503-9 - PubMed
    1. J Clin Oncol. 1988 Jan;6(1):98-105 - PubMed

Publication types